financetom
Business
financetom
/
Business
/
Elbit Systems' Q1 Revenue Jumps 22%, Backlog Swells To $23.1 Billion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Elbit Systems' Q1 Revenue Jumps 22%, Backlog Swells To $23.1 Billion
May 26, 2025 10:52 AM

Elbit Systems Ltd ( ESLT ). shares are trading higher in the premarket on Tuesday after the company reported better-than-expected first-quarter 2025 results.

The revenue for the quarter stood at $1.9 billion, beating the consensus of $1.69 billion.

Adjusted EPS rose to $2.57 from $1.81 a year ago, beating the consensus of $2.30.

Segment revenues YoY: Aerospace $504 million (+20%), C4I and Cyber $220 million (+12%), ISTAR and EW $361 million (+4%), Land $560.8 million (+48%) and, Elbit Systems ( ESLT ) of America (ESA) $404.2 million (+18%).

Adjusted gross margin contracted to 24.3% from 24.7% a year ago, and adjusted operating margin expanded to 8.7% from 7.8% in the same quarter last year.

As of March 31, 2025, the order backlog stood at $23.1 billion, with 66% from outside Israel and 51% scheduled for the remainder of 2025 and 2026. 

Cash provided by operating activities for the first quarter totaled $183.6 million, vs. cash flow used in operating activities of $6.4 million a year ago quarter.

Dividend: The board declared a dividend of 60 cents per share, payable on July 7, to the shareholders of record on June 24, 2025.

The company disclosed that since the Hamas attack on Oct. 7, 2023, Elbit Systems ( ESLT ) has seen significantly increased demand from the Israel Ministry of Defense.

Elbit ( ESLT ) CEO Bezhalel (Butzi) Machlis says the company secured significant contracts worldwide. “Our global presence and diversified portfolio position us well to capture increasing global defense budgets,” he added.

Price Action: ESLT shares are up 2.79% at $416.70 premarket at the last check on Tuesday.

Read Next:

Nokia Trials Advanced 5G Defense Solutions In Norwegian Military Exercise

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Saratoga Q1 adjusted NII per share rises 17.9% on sequential basis
Saratoga Q1 adjusted NII per share rises 17.9% on sequential basis
Jul 8, 2025
Overview * Saratoga fiscal Q1 adjusted NII per share rises 17.9% on sequential basis * NAV increases 0.9% on sequential basis , reflecting portfolio performance * Company's LTM ROE of 9.3% beats BDC industry average of 7.0% Outlook * Saratoga Investment ( SAR ) cautious on new commitments amid volatility Result Drivers * NII INCREASE - 17.9% rise in adjusted...
Roblox Insider Sold Shares Worth $615,480, According to a Recent SEC Filing
Roblox Insider Sold Shares Worth $615,480, According to a Recent SEC Filing
Jul 8, 2025
04:22 PM EDT, 07/08/2025 (MT Newswires) -- Matthew D Kaufman, Chief Safety Officer, on July 03, 2025, sold 6,000 shares in Roblox ( RBLX ) for $615,480. Following the Form 4 filing with the SEC, Kaufman has control over a total of 313,223 Class A common shares of the company, with 313,223 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1315098/000131509825000235/xslF345X05/wk-form4_1752005886.xml ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Solid Biosciences Gets FDA, Health Canada Clearance to Advance Gene Therapy Trial for Cardiac Disease
Solid Biosciences Gets FDA, Health Canada Clearance to Advance Gene Therapy Trial for Cardiac Disease
Jul 8, 2025
04:25 PM EDT, 07/08/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said late Tuesday it received approval for its investigational new drug application from the US Food and Drug Administration and clinical trial application from Health Canada for SGT-501, a gene therapy to treat catecholaminergic polymorphic ventricular tachycardia, a rare, life-threatening genetic heart rhythm disorder. The company said it...
Copyright 2023-2026 - www.financetom.com All Rights Reserved